<DOC>
	<DOC>NCT01376154</DOC>
	<brief_summary>The purpose of this study is to confirm efficacy and safety when administering lamivudine tablet alone in subjects with hepatitis B virus-induced liver cirrhosis.</brief_summary>
	<brief_title>Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Subjects with hepatitis B virusinduced liver cirrhosis, in whom lamivudine tablet was administered alone for 6 months or longer, or those in whom lamivudine tablet was expected to be administered alone for 6 months or longer Subjects previously enrolled in Drug Use Investigation or Special Drug Use Investigation of lamivudine tablet Subjects with a history of hypersensitivity of the ingredients of lamivudine tablet</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>